- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01065389
Resistance Training in Intradialysis Patients (DIAPRE)
September 8, 2013 updated by: Mr. Baskaran Chandrasekaran, Sikkim Manipal University
Phase 1 RCT of Progressive Resistance Training on Small Solute Clearance, Functional Capacity and Quality of Life in Intradialysis Patients
Dialysis patients usually have peripheral muscle weakness due to metabolic disturbances (increased protein catabolism) and fatigue.
This muscle weakness may decrease functional capacity and quality of life.
It also serves to increase cardiovascular risk factors in these end stage renal disease patients.
Peripheral muscle strength training shall combat physical inactivity during dialysis.
In the investigators trial, the investigators hypothesis that peripheral muscle training might regulate protein catabolic rate,renal functions, cardiovascular risk factors, improve functional capacity and quality of life in endstage renal disease patients undergoing dialysis.
Study Overview
Status
Unknown
Conditions
Detailed Description
End stage renal failure patients undergoing dialysis have profound muscle wasting, reduced functional capacity and quality of life due to uremia, steroids, frequent dialysis and fatigue.
During dialysis, physical inactivity further deteriorates the patient's functional capacity.
Aerobic or strength training may combat this physical inactivity.
It may also improve the functional capacity and quality of life.
Recent studies have claimed the benefits of resistance exercises in improving functional capacity.
But they have not documented effects on kidney function (electrolyte and urea kinetics) and muscle wasting (protein catabolic rate).
In our trial, we attempt to study the effects of resistance training in improvement of renal function and muscle wasting apart from functional capacity and quality of life in dialysis patients
Study Type
Interventional
Enrollment (Anticipated)
46
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sikkim
-
Gangtok, Sikkim, India, 737102
- Central Referral Hospital, SMIMS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 60 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have end stage renal disease (diagnosed and the stage graded by nephrologist or the intensivist concerned) for more than 6 months and dialysis for at least 3 months (the impact of exercise training can be easily assessed)
- Must be between the ages of 30 - 60 years of age/ both genders.
- Must be able to understand the purpose of exercise testing and resistance training.
Exclusion Criteria:
- Those with acute nephritic syndrome and hematuria < 2 months.
- Those with profound anemia and blood transfusion < 2 months
- Those underwent renal transplantation < 6 months.
- Those receiving/ received cytotoxic drugs - amiloride, azathioprine/ aspirin (antiplatelets)< 2 months
- Those with coagulation disorders or under anticoagulants < 4 months.
- Those underwent recent cardiac surgeries and with recent unstable cardiac failures
- Those with recent cerebrovascular accidents < 6 months
- Those have recent urinary tract infections, Renal and bladder carcinomas < 2 months
- Those with absolute contraindications for resistance exercise training (as per American College of Sports Medicine.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Prgressive Resistance Exercise Training
Progressive Resistance Exercise Training thrice a week for 12 weeks.
For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
|
Progressive Resistance Exercise Training thrice a week for 12 weeks.
For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
Other Names:
|
ACTIVE_COMPARATOR: Unstructured Resistance Exercise
Unstructured Resistance Exercise thrice a week for 12 weeks.
For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
|
Unstructured Resistance Exercise 30 minutes a day, thrice a week for 12 weeks.
For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum and Urea biochemistry - electrolytes (Na, K+), serum albumin, inflammatory markers, urea kinetics, protein catabolic rate
Time Frame: Bimonthly
|
Bimonthly
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximal Oxygen Consumption (VO2 max) and Heart Rate Recovery through Queens College step test
Time Frame: Once Monthly
|
Once Monthly
|
Fat levels by skin fold measurements
Time Frame: Once monthly
|
Once monthly
|
Handgrip strength by dynamometer
Time Frame: Once monthly
|
Once monthly
|
Six minute walk test distance
Time Frame: Once monthly
|
Once monthly
|
Quality of life (KDQOL - SF questionnaire)
Time Frame: Once monthly
|
Once monthly
|
Depression (Beck Depression Questionnaire)
Time Frame: Once monthly
|
Once monthly
|
Lactate Threshold
Time Frame: Once monthly
|
Once monthly
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Baskaran Chandrasekaran, MPT, Lecturer / Consultant cardiopulmonary Physiotherapist
- Study Chair: Bidhan C Sharma, MPT, Assistant Professor/ Consultant Physiotherapist
- Study Chair: Manish Goon, BPT, Clinical Physiotherapist
- Study Chair: Nikita Joshi, MPT, Head of Department/ Associate Professor
- Study Chair: Arpan Battacharia, MD, Dialysis Unit Incharge
- Study Director: Bidita Kandelwal, MD, Head of Medicine Department
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (ANTICIPATED)
April 1, 2015
Study Completion (ANTICIPATED)
August 1, 2016
Study Registration Dates
First Submitted
February 4, 2010
First Submitted That Met QC Criteria
February 8, 2010
First Posted (ESTIMATE)
February 9, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
September 10, 2013
Last Update Submitted That Met QC Criteria
September 8, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTRI/2010/091/000014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Iperboreal Pharma SrlWithdrawnEnd-Stage Renal Disease
-
Cubist Pharmaceuticals LLCCompleted
-
Medical University of GrazWithdrawnEnd-stage Renal DiseaseAustria
-
Janssen Research & Development, LLCBayerCompleted
-
Chulalongkorn UniversityCompletedEnd-stage Renal DiseaseThailand
-
University of KansasCompletedEnd-Stage Renal Disease
-
Eisai Co., Ltd.CompletedEnd-Stage Renal DiseaseJapan
Clinical Trials on Progressive Resistance Exercise Training
-
Bangor UniversityBetsi Cadwaladr University Health BoardCompletedChronic Kidney DiseaseUnited Kingdom
-
Danish Head and Neck Cancer GroupCompleted
-
Hugo W. Moser Research Institute at Kennedy Krieger...National Multiple Sclerosis SocietyCompletedMultiple SclerosisUnited States
-
University of Kansas Medical CenterRecruiting
-
Pamukkale UniversityCompletedTotal Knee ArthroplastyTurkey
-
Dana-Farber Cancer InstituteNational Institute on Aging (NIA)Recruiting
-
Indiana UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
Stian EllefsenSykehuset Innlandet HFRecruiting
-
University of SydneyCompleted
-
University of Illinois at ChicagoNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingHypertension | Sarcopenia | High Blood PressureUnited States